GENinCode (LSE:GENI) Receivables Turnover : 2.25 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. GENinCode's Revenue for the six months ended in Jun. 2024 was £1.39 Mil. GENinCode's average Accounts Receivable for the six months ended in Jun. 2024 was £0.62 Mil. Hence, GENinCode's Receivables Turnover for the six months ended in Jun. 2024 was 2.25.

GENinCode Receivables Turnover Historical Data

The historical data trend for GENinCode's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Receivables Turnover Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

3.59

4.87

5.21

5.81

GENinCode Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Receivables Turnover	Get a 7-Day Free Trial					1.81	1.88	1.89	2.17	2.25

Competitive Comparison of GENinCode's Receivables Turnover

For the Diagnostics & Research subindustry, GENinCode's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode's Receivables Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where GENinCode's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

GENinCode Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

GENinCode's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	2.16	/ (	(0.315	+	0.428)	/	2 )
=	2.16	/	0.3715
=	5.81

GENinCode's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

	Receivables Turnover (Q: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Jun. 2024 ))	/	count )
=	1.389	/ (	(0.428	+	0.805)	/	2 )
=	1.389	/	0.6165
=	2.25

GENinCode (LSE:GENI) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

GENinCode Receivables Turnover Related Terms

Thank you for viewing the detailed overview of GENinCode's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

9PL:Germany

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.